Q1 EPS Forecast for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright boosted their Q1 2025 earnings estimates for shares of Corcept Therapeutics in a research report issued on Tuesday, February 11th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.55 for the quarter, up from their prior estimate of $0.36. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $2.51 EPS, FY2026 earnings at $4.37 EPS, FY2027 earnings at $6.36 EPS and FY2028 earnings at $7.67 EPS.

A number of other brokerages have also weighed in on CORT. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $88.25.

Corcept Therapeutics Stock Up 3.0 %

Shares of NASDAQ CORT opened at $70.15 on Thursday. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 55.68 and a beta of 0.58. The company’s 50-day simple moving average is $57.45 and its 200-day simple moving average is $48.88. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $71.29.

Insiders Place Their Bets

In other news, insider Joseph Douglas Lyon sold 1,411 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the sale, the insider now owns 8,494 shares in the company, valued at $481,779.68. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,011 shares of company stock valued at $1,479,608 in the last three months. 20.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently modified their holdings of the business. Black Diamond Financial LLC raised its holdings in Corcept Therapeutics by 4.0% in the 4th quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 200 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Corcept Therapeutics by 9.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 257 shares during the last quarter. Hancock Whitney Corp boosted its position in shares of Corcept Therapeutics by 1.2% during the 3rd quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 270 shares during the period. Arizona State Retirement System increased its holdings in Corcept Therapeutics by 1.1% in the 4th quarter. Arizona State Retirement System now owns 27,270 shares of the biotechnology company’s stock valued at $1,374,000 after purchasing an additional 289 shares during the last quarter. Finally, Illinois Municipal Retirement Fund increased its holdings in Corcept Therapeutics by 0.8% in the 4th quarter. Illinois Municipal Retirement Fund now owns 47,527 shares of the biotechnology company’s stock valued at $2,395,000 after purchasing an additional 368 shares during the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.